Matarin Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Matarin Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-88,611	Closed	-$6.21M	–	294
2019 Q1	$6.21M	Buy	+88,611	New	+$6.57M	0.45%	86
2013 Q3	–	Sell	-2,376	Closed	-$75K	–	226
2013 Q2	$75K	Buy	+2,376	New	+$78K	0.08%	198

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Matarin Capital Management's GHDX Position: Q2 2019 in Review

Matarin Capital Management sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 88,611 shares — an estimated $6.21M sold.

Matarin Capital Management first reported a position in GHDX in Q2 2013 and held it in 2 quarters. The position peaked at $6.21M in Q1 2019. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

Matarin Capital Management reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
Matarin Capital Management sold 88,611 Genomic Health, Inc. shares in Q2 2019, an estimated $6.21M.
Matarin Capital Management first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 2 quarters.
Matarin Capital Management's Genomic Health, Inc. position peaked at $6.21M in Q1 2019.
215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Matarin Capital Management's 13F filing for Q2 2019, filed 8 Aug 2019.